BioSpace News Archive

Immuron Limited is pleased to announce that the US Naval Medical Research Command (NMRC) has initiated the clinical evaluation of a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC) developed in collaboration with Immuron.

Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares (“Shares”) of common stock of POINT Biopharma Global Inc.

Trevena, Inc. today announced a poster presentation at the 62nd Annual Meeting for the American College of Neuropsychopharmacology (ACNP). The conference is being held from December 3rd to 6th, 2023.

SciBase Holding AB, a leading developer of augmented intelligence-based solutions for skin disorders announced that it will continue its US coast-to-coast momentum with a collaboration agreement with the Skin and Cancer Reconstructive Surgery Center in California.

Cancer Research UK, one of the world’s largest charitable funders of cancer research, its innovation unit, Cancer Research Horizons, and Guardant Health, Inc., a leading precision oncology company, announced a collaboration to explore the sharing of technologies, data, and insights to advance the development and precision of cancer detection and treatment.

Zura Bio Limited announced two abstracts were accepted and presented at World Allergy Congress, held December 1 – 3, 2023 in Bangkok, Thailand.

Caris Life Sciences® announced that the company and collaborators within the Caris Precision Oncology Alliance™ will collectively present findings at the San Antonio Breast Cancer Symposium that illustrate the potential impact of molecular profiling on the treatment of breast cancer.

The Joint Corp. (NASDAQ: JYNT), the nation’s largest provider of chiropractic care through The Joint Chiropractic ® network, announced that management is scheduled to attend the 12th Annual Roth Deer Valley Conference on December 14th and 15th.

Chimerix today announced the promotion of Michelle LaSpaluto, Vice President of Corporate Financial Planning and Investor Relations, to Chief Financial Officer effective December 1, 2023.

Jaguar Health, Inc., under its Jaguar Animal Health tradename for the veterinary market, announced that the U.S. Food and Drug Administration has approved renewal of Canalevia-CA1.